Number of serious adverse events · patients with osteoarthritis
Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
COX‐2 NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.92 [0.14, 6.21]
669 participants
Moderate
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.69 [0.36, 7.97]
671 participants
Moderate
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Long‐term serious adverse events · patients with rheumatoid arthritis
1 finding from 1 review
Serious adverse events(12 months) · children and young people with JIA
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Serious adverse events at longest · participants with gallstone disease (cholesterol, pigment, or mixed)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in serious adverse events at longest (low certainty).
1 finding from 1 review
Safety Any serious adverse event · HMB
Endometrial resection or ablation showed no clear difference in safety Any serious adverse events compared with open hysterectomy (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events at maximum · patients without heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (12 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
1 finding from 1 review
Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Intervention not reported
Short‐term serious adverse events · people with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events by 6 weeks · people with agitation in dementia
It is very uncertain whether valproate preparations changes serious adverse events by 6 weeks compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: infection · people with implantable ventricular assist devices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: mortality · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Short‐term serious adverse events · patients with rheumatoid arthritis
Celecoxib showed no clear difference in short‐term serious adverse events compared with traditional NSAIDs (low certainty).
1 finding from 1 review